![](https://rt.prnewswire.com/rt.gif?NewsItemId=AE66677&Transmission_Id=202407221307PR_NEWS_ASPR_____AE66677&DateId=20240722)
Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million
Grünenthal acquires Valinor Pharma in an all-stock deal and becomes the owner of the global rights to Movantik® (naloxegol) Valinor Pharma had owned Movantik since early 2023 and leveraged Apollo Care’s commercial platform to grow Movantik volume in the U. …